Quality Cancer Care Alliance’s Nationwide Network of Independent Community Oncology Practices Welcomes Comprehensive Hematology Oncology, LLC, With Eight Locations Serving St. Petersburg-Tampa Bay Communities
PUYALLUP, Wash., October 26, 2023 (Newswire.com)
-
Quality Cancer Care Alliance Network (QCCA) is pleased to announce the addition of the independent physician-led and patient-centered practice Comprehensive Hematology Oncology, LLC, located in St. Petersburg, Florida, as the 20th practice to join QCCA’s national clinically integrated network of independently owned and operated oncology and hematology practices located across the United States. The addition of CHO brings QCCA’s membership to 419 oncology and hematology practitioners at 20 practices in 16 locations across the country.
“Independent practices like ours take pride in providing personalized, cost-effective, yet standardized and NCCN-guided care. We go above and beyond to take care of our patients without the burden of extra layers of bureaucracy, and QCCA provides us the power of unity. We have a saying: 'It is easy to break a single twig but hard to break twigs tied up in a bundle.' Together, we strengthen each other’s organizations,” says Dr. Pratibha Desai, MD, MPH, founding partner of Comprehensive Hematology Oncology, LLC, about its membership in QCCA. “We are very much looking forward to consolidating our resources and expanding our work in research as well as better managing our data and streamlining many processes, and look forward to working together with the QCCA team.”
“As we work toward more effective, cost-efficient ways to improve the quality of the care, and expand our research work across our membership, our collaborative builds on the strengths and expertise of its many members serving diverse communities across the country. Welcoming Comprehensive Hematology Oncology to our team furthers that mission and expands our network from the Atlantic to the Gulf Coast of Florida,” said Sibel Blau, MD, President and CEO of QCCA Network. “We are delighted to have this fiercely independent group join our network.”
QCCA is the only fully independent, clinically integrated national oncology network that brings together practices under a collaborative relationship, without acquisition or consolidation under a single tax identification structure. As such, members can continue to focus on their individual missions while being able to use collaborative tools to utilize clinical pathways and share data for more effective and cost-efficient ways to improve the quality of care and expand and increase access to trials under an organized research network.
While traditional eye drop bottles require hand-eye coordination and deliver four to five times more medication than the human eye can hold, the Optejet® dispenser's human-centric design administers an easier, more accurate and appropriate dose directly where it is needed in the eye.
Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, brings human-centric design to ophthalmology with its novel Optejet® dispenser.
Traditional eye drops normally overdose the patient's eye with medication and preservatives. Eyenovia's easy-to-use, novel Optejet® dispenser administers precisely 8µL of medication to the eye, effectively treating the patient's condition while creating a more gentle dosing experience.
"The unique delivery mechanism of the Optejet® will fundamentally change how we think about eye medication," said Michael Rowe, CEO of Eyenovia. "Right now, traditional eye drops can result in significant dose-related side effects for the treatment of chronic illnesses like glaucoma. The Optejet® dispenser is designed for patients to experience easier administration and fewer side effects with similar efficacy."
The Optejet® dispenser administers ophthalmic solutions horizontally using Eyenovia's proprietary Microdose Array Print (MAP™) technology. The system functions similar to an inkjet printer, delivering accurate microdoses through a precision spray. Traditional eye drops deliver four to five times larger volume than the human eye can actually hold, which causes eye drops to roll down the face and overdose the eye with preservatives.
Poor delivery of eye drops is more than an inconvenience; it can prevent patients from using necessary medication because of the side effects. For example, with medication to help dilate the pupils for eye exams, up to 23% of patients experienced stinging and burning with the eye drops, causing patients to forgo eye exams. In Eyenovia studies, less than 1% of patients experienced stinging and burning.
"Medications only work if patients take them, and with the Optejet, we have designed a way for patients to benefit from an easy-to-use, appropriate, lower dose spray that results in similar efficacy. We're excited for physicians and providers to be able to offer this revolutionary technology in the near future to patients who deserve a more positive experience," said Rowe.
Eyenovia's first marketed invention is expected to be MydCombi™, a first-in-class drug-device combination microdose for in-office pupil dilation. This potentially will help save physician's chair time, eliminating the traditional three eyedrops used for a patient's eye exam. Other exciting innovations in the Eyenovia pipeline include MicroLine (for the treatment of Presbyopia) and MicroPine (for the treatment of Myopia).
Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia, and myopia progression. For more information, visit www.eyenovia.com.
Forward-Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents that we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws. Eyenovia does not undertake any obligation to update any forward-looking statements.
Eyenovia Contact:
Eyenovia, Inc. John Gandolfo Chief Financial Officer [email protected]
